TY - JOUR
T1 - Circulating cell-specific extracellular vesicles as biomarkers for the diagnosis and monitoring of chronic liver diseases
AU - Newman, Lauren A.
AU - Muller, Kate
AU - Rowland, Andrew
PY - 2022/5
Y1 - 2022/5
N2 - Chronic liver diseases represent a burgeoning health problem affecting billions of people worldwide. The insufficient performance of current minimally invasive tools is recognised as a significant barrier to the clinical management of these conditions. Extracellular vesicles (EVs) have emerged as a rich source of circulating biomarkers closely linked to pathological processes in originating tissues. Here, we summarise the contribution of EVs to normal liver function and to chronic liver pathologies; and explore the use of circulating EV biomarkers, with a particular focus on techniques to isolate and analyse cell- or tissue-specific EVs. Such approaches present a novel strategy to inform disease status and monitor changes in response to treatment in a minimally invasive manner. Emerging technologies that support the selective isolation and analysis of circulating EVs derived only from hepatic cells, have driven recent advancements in EV-based biomarker platforms for chronic liver diseases and show promise to bring these techniques to clinical settings.
AB - Chronic liver diseases represent a burgeoning health problem affecting billions of people worldwide. The insufficient performance of current minimally invasive tools is recognised as a significant barrier to the clinical management of these conditions. Extracellular vesicles (EVs) have emerged as a rich source of circulating biomarkers closely linked to pathological processes in originating tissues. Here, we summarise the contribution of EVs to normal liver function and to chronic liver pathologies; and explore the use of circulating EV biomarkers, with a particular focus on techniques to isolate and analyse cell- or tissue-specific EVs. Such approaches present a novel strategy to inform disease status and monitor changes in response to treatment in a minimally invasive manner. Emerging technologies that support the selective isolation and analysis of circulating EVs derived only from hepatic cells, have driven recent advancements in EV-based biomarker platforms for chronic liver diseases and show promise to bring these techniques to clinical settings.
KW - Chronic liver disease
KW - Extracellular vesicles
KW - Metabolic-associated fatty liver disease
KW - Minimally invasive biomarkers
KW - Non-alcoholic fatty liver disease
KW - Tissue-specific biomarkers
UR - http://www.scopus.com/inward/record.url?scp=85127841939&partnerID=8YFLogxK
UR - http://purl.org/au-research/grants/NHMRC/1158210
U2 - 10.1007/s00018-022-04256-8
DO - 10.1007/s00018-022-04256-8
M3 - Review article
C2 - 35397694
AN - SCOPUS:85127841939
VL - 79
JO - Cellular and Molecular Life Sciences
JF - Cellular and Molecular Life Sciences
SN - 1420-682X
IS - 5
M1 - 232
ER -